转移性结肠癌患者应用升血汤联合Xelox化疗方案治疗的价值分析  

Value Analysis of Shengxue Decoction Combined with Xelox Chemotherapy for Patients with Metastatic Colon Cancer

作　　者：赵勇 张慧彬 于宏环 余自然 ZHAO Yong;ZHANG Huibin;YU Honghuan;YU Ziran(Xunxian People’s Hospital,Henan Junxian 456250,China)

机构地区：[1]河南省浚县人民医院消化肿瘤科,河南浚县456250

出　　处：《中医药临床杂志》2020年第9期1742-1745,共4页Clinical Journal of Traditional Chinese Medicine

摘　　要：目的:探讨转移性结肠癌患者应用升血汤联合Xelox化疗方案治疗的价值。方法:选取82例转移性结肠癌患者为研究对象,使用随机化法将其分为对照组和观察组,每组各41例。对照组行Xelox方案化疗,观察组在对照组的基础上加用升血汤治疗,共治疗21d。比较2组患者临床疗效、免疫功能情况和不良反应发生情况。结果:观察组的有效率为92.68%显高于对照组75.61%,不良反应发生率低于对照组;CD3+、CD4+水平观察组高于对照组,CD8+水平低于对照组,差异均有统计学意义。结论:升血汤联合Xelox方案化疗治疗转移性结肠癌患者临床疗效显著,可明显改善患者免疫功能,降低不良反应的发生。Objective:To explore the value of Shengxue decoction combined with Xelox chemotherapy regimen in the treatment of patients with metastatic colon cancer.Methods:82 patients with metastatic colon cancer were selected as the research objects,and they were divided into a control group and an observation group by randomization,with 41 cases in each group.The control group received Xelox chemotherapy,and the observation group was treated with Shengxue decoction on the basis of the control group for a total of 21 days.The clinical efficacy,immune function and adverse reactions of the two groups were compared.Results:The effective rate of the observation group was 92.68%,which was significantly higher than that of the control group 75.61%,and the incidence of adverse reactions was lower than that of the control group;the CD3+ and CD4+ levels of the observation group were higher than the control group,and the CD8+ level was lower than the control group.The difference was statistically significant.significance.Conclusion:Shengxue decoction combined with Xelox chemotherapy has a significant clinical effect in the treatment of patients with metastatic colon cancer,which can significantly improve the immune function of patients and reduce the occurrence of adverse reactions.

关 键 词：升血汤 Xelox方案化疗 转移性结肠癌 免疫功能 

分 类 号：R735.35[医药卫生—肿瘤]